P
Protalix
Recombinant Therapeutics Proteins Using Plant Cell-Based Expression System
About Protalix
Protalix is a biopharmaceutical company specializing in the development, production, and commercialization of recombinant therapeutic proteins using its proprietary ProCellEx plant cell-based protein expression system. The company focuses on creating potentially superior versions of existing therapeutic proteins, targeting established pharmaceutical markets. Protalix serves patients with respiratory diseases and rare conditions such as Fabry disease. Its business model revolves around advancing its pipeline through clinical trials and eventually bringing these therapies to market. Revenue is generated through the commercialization of these therapeutic proteins, either directly or through partnerships with other pharmaceutical companies.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 1994
- Headquarters
- Karmiel, Israel
- Listing
- IPO 1997
- Sector
- Biotech & Life Sciences
- Power Law
- Colt$25–100M revenue
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
- OSOffice of the Chief Scientist
Series B and later6 investors entered at this stage
UBS- HMHighbridge Capital Management
Rosalind Capital Partners- PHPsagot Investment House
More Investment House- APAlrov Properties
Source: Dealroom Talent Intelligence.
Global footprint
across markets
Market sentiment
An AI-synthesised read of the highest-engagement posts about Protalix on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Protalix on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.